The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: -108.00 (-0.87%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Equities still choppy, but then a vaccine...

Mon, 28th Sep 2020 14:04

* European shares rebound

* Banks lead sectoral gainers, up 4.6%

* Eyes on William Hill after bid proposal

* Wall St futures higher
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) and Danilo Masoni (danilo.masoni@thomsonreuters.com) in
Milan.

EQUITIES STILL CHOPPY, BUT THEN A VACCINE ... (1304 GMT)

We shouldn’t worry about European equities as a recent choppy and sometimes unpredictable
trend might not last long.

Despite surging coronavirus cases coupled with concerns about the economic recovery, Morgan
Stanley sees some light at the end of the tunnel as a vaccine is about to come.

September was tricky if not scary as the market had to digest uncertainty related to fresh
U.S. fiscal stimulus, Brexit and the coronavirus outbreak.

“With each of these issues remaining ‘live’ in the near term” MS expects stocks to remain
choppy for a while, a research note says, adding they are not oversold yet.

The medium term outlook is a positive one as Morgan Stanley expects possible good news on
the vaccine front in Q4.

Morgan Stanley analysts expect “pivotal data for three covid-19 vaccines to begin reporting
in October or November.”

The AstraZeneca vaccine is most important as it has a "potential for 700 million
doses to be available by the end of 2020 (three billion doses by the end of 2021), which opens
up the possibility of mass vaccination programs starting as early as 1Q21."

(Stefano Rebaudo)

*****

DANCING WITH THE BOE, HUMMING WITH BREXIT (1227 GMT)

Who said Mondays are dull?

There's music and dancing across the UK newsflow today with both Brexit and negative rates
providing some background entertainment for the rising pound.

First, as noted by Gilles Moëc, chief economist at AXA Investment Managers, there's
"positive mood music in the British press on the chances of a Free Trade Agreement between
London and Brussels."

Funny to note that we also got an EU diplomat using the same expression in a story today
.

"The mood music was a bit better", that diplomat said, noting Britain's Brexit supremo
Gove's confidence about securing a deal, which came after Barnier's said he was determined to
clinch an agreement last week.

As for the dancing, it's provided courtesy of the BoE!

BoE policymaker Silvana Tenreyro defended negative rates in a newspaper interview over the
weekend, a move which Neil Wilson at Markets.com called "a careful piece of choreography to
communicate the bank’s shift towards a state of outright financial repression".

If the BoE is indeed dancing one step forward, one step backward, then Bank of England
Deputy Governor Dave Ramsden surely qualifies as a good tango partner.

"For me, I see the effective lower bound still at 0.1 which is where Bank Rate is at
present," Ramsden said in an interview with Britain's Society of Professional Economists posted
online today.

So while BoE rate setters are blowing hot and cold on negative rates, there's a lot being
written about the possible impact of negative rates.

George Lagarias, chief economist at Mazars, for instance sees the strategy as a double-edged
sword which on one hand could help prevent an vicious economic cycle, but which could on the
other hand be devastating for the balance sheets of British banks.

"European Banks, who for years have endured negative rates and have been one of the worst
sectors globally, can attest to that", he said, adding that investors might decide not to jump
into risky investments despite the policy change.

And that's actually the point of a Reuters analysis published earlier this month which
showed that negative rates can be ineffectual and perhaps even counterproductive.

Here's the story:

ANALYSIS-"Don't do it" -studies flash sub-zero rate warnings to central banks

And more reading:

Britain, EU start key week of Brexit talks with 'better mood music'

UPDATE 2-Bank of England's Ramsden sees floor for rates above zero

UPDATE 1-BoE's Tenreyro says evidence on negative rates is "encouraging"

(Julien Ponthus and Elizabeth Howcroft)

*****

WORRIED ABOUT A STRONGER DOLLAR? BET ON DRUGS (1041 GMT)

Over the last 15 years there looks to have been an inverse correlation between global stocks
and the dollar, and if history is any guide, the recent signs of the greenback bottoming out may
not be a good omen.

"This is especially if the USD rebound is coupled with stalling PMIs, as seen last week in
Europe, a rollover in EPS revisions, weaker oil price, peaking inflation breakevens, as well as
bond yields remaining stuck in a range," JPMorgan says.

But of course there are exceptions, namely EU exporters, and at this point it time,
strategists at the U.S. bank say they're "particularly bullish" on healthcare.

European healthcare makes 71% of its revenues abroad, its performance has historically been
closely aligned to the dollar, and currently the sector is enjoying cheap valuations and strong
earnings momentum, JPMorgan notes.

(Danilo Masoni)

*****

GOLD MIGHT BE READY TO SHINE AGAIN (0954 GMT)

It doesn’t seem to be the case this morning with European stocks showing strong resilience
after the banking index hit an all-time low on Friday, but some analysts say risk sentiment is
low and suggest adding gold to portfolios.

According to UBS, gold staged a temporary correction but it could reach the $2,000/oz mark
by year end.

The investment bank mentions three reasons, which will favour the yellow metal while
weakening the U.S. dollar in the near future.

First with U.S. election looming and after the battle over the Supreme Court nomination the
chances of approval of a fresh stimulus package are abating and this will push the Fed to keep
interest rates low for longer.

Then a contested outcome is possible in the U.S. election “which could add to further
volatility and result in safe-haven flows, though more into gold, the Swiss franc, and the
Japanese yen than the US dollar,” a UBS research note says.

Since gold is priced in U.S. dollar, a greenback fall supports the yellow metal.

Besides central banks are ready to tolerate higher inflation and gold offers an hedge
against it “as a ‘real asset’.”

Below gold and dollar moving the opposite direction during summer

(Stefano Rebaudo)

*****

TACTICAL ON CYCLICALS (0928 GMT)

Looking at cyclicals rallying this morning across Europe, the idea to cool off exposure
might sound rather counter-intuitive.

But according to Sylvain Goyon, a strategist at Oddo, "it not absurd to consider a tactical
pause" given that the market might start worrying about the resurgence of the pandemic and the
curve of the V-shaped recovery losing steam amid disappointing PMIs.

Say you actually fear the economy is losing momentum and feel it is indeed time to sell some
exposure, what should you do with the cash?

Why not buy a long position on the VIX which would stretch beyond the U.S. November
election, asks Goyon who nevertheless stresses that the thing about a tactical retreat is that
it is, by definition, a temporary move.

"Neither the pandemic nor the electoral suspense in the U.S. invalidate the drivers behind
our call on valuation convergence in favor of cyclicals versus defensive and value versus
growth".

(Julien Ponthus)

*****

BANKS REBOUND FROM RECORD LOWS, BARGAIN HUNTERS BUYING THE DIP (0839 GMT)

European equities are staging a broad bounce-back this morning with all sectors trading in
the black, as it seems investors are hunting for bargains following Friday's sell-off.

And talking about bargains, banks spring to mind, so it's not a big surprise to see
them leading the advance with a 4% surge.

But if you put today's rally in the context of the sector hitting its latest new record low
on Friday, there's much less to rejoice about. And with the prospect of interest rates staying
lower for longer, any quick reversal in the industry's fortunes just looks highly unlikely.

And here you can see how cheap are European banks, currently trading at a record low
price-to-book value of less than 0.5.

(Danilo Masoni)

*****

OPENING SNAPSHOT: STRONG REBOUND, BANKS SHINE (0739 GMT)

European stocks are higher as newsflow on the M&A front as well as on some banks is
supporting a rebound after recent falls.

ArcelorMittal shares are up 6% after striking a deal to sell its U.S. assets, while
shares in Commerzbank are up 4.8% as the nomination of the new CEO paves the way for
an overhaul that could close hundreds of branches and shrink its foreign operations.

HSBC stocks, up 9.8%, are following the gains of Hong Kong listed shares,
after the bank’s biggest shareholder Ping An Insurance Group Co of China bought additional
shares in the British bank to take its stake to 8% from 7.95%.

The STOXX 600 is up 1.5%, with banking stock index up 4.2%, after hitting a fresh
all-time low on Friday.

Almost a mute reaction by Suez shares, up 0.8%, after Veolia said it would improve
its offer.

William Hill stocks are down 10% after Friday’s jump, as Caesars Entertainment
said it was in advanced talks about a possible cash offer that values the British
bookmaker at about 2.9 billion pounds.

Risk sentiment is showing some resilience as investors focus on stimulus plans by
governments and central banks.

(Stefano Rebaudo)

*****

ON THE RADAR: M&A ON THE FRONTLINE, COMMERZBANK (0640 GMT)

European stocks are poised to open higher supported by a tech shares rebound on Wall Street
on Friday and strong Chinese data during the weekend.

Risk sentiment continues to show some resilience as investors are focused on stimulus plans
by governments and central banks.

Cleveland-Cliffs, the largest U.S. producer of iron ore pellets, said it had agreed
to buy the U.S. assets of world's largest steelmaker ArcelorMittal for about $1.4
billion.

U.S. casino operator Caesars Entertainment said it was in advanced talks with
William Hill about a possible cash offer that values the British bookmaker at about 2.9
billion pounds.

French utility group Veolia will improve its offer to buy the bulk of Engie's
stake in smaller rival Suez by September 30. Veolia last month offered 2.9
billion euros for a 29.9% stake in Suez owned by Engie, with a view to subsequently taking full
control of Suez by buying up more shares.

Shares in Commerzbank are up 4.4% in early trade after the nomination of Manfred
Knof as chief executive of Germany's bank, which paves the way for an overhaul that could close
hundreds of branches and shrink its foreign operations, though any major changes may still take
months to formalise.

Investors welcomed former Daimler chief executive Dieter Zetsche's decision to
forego his role as chairman of the German carmaker, announced at the weekend and starting a race
to find an independent head of the company's supervisory board.

Rio Tinto is willing to continue talks with the New Zealand government on
extending operations at its Tiwai Point aluminium smelter.

Sonova expects to return to growth in the second half of the year.

Eyes also on Diageo which said its business was performing ahead of its
expectations.

(Stefano Rebaudo)

*****

MORNING CALL: RESILIENT AFTER RECENT FALLS (0533 GMT)

European stock futures are well in the black showing some resilience after recent falls and
a tech shares rebound on Wall Street on Friday, though broad sentiment remain cautious.

Asian stocks are higher after profits at China’s industrial firms grew for the fourth
straight month in August, but concerns about surging coronavirus cases in Europe and risks of
new restrictive measures continue to weigh.

However there is more going on as investors’ focus is on UK-Europe post-Brexit trade talks
and a fresh U.S. stimulus package, which by the way seems increasingly unlikely to be approved
before the November presidential election.

(Stefano Rebaudo)

*****

More News
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
18 Apr 2024 14:17

UK earnings, trading statements calendar - next 7 days

Friday 19 April 
888 Holdings PLCTrading Statement
Man Group PLCTrading Statement
Monday 22 April 
Brave Bison Group PLCFull Year Results
Elixirr International PLCFull Year Results
Frenkel Topping Group PLCFull Year Results
Mobico Group PLCFull Year Results
South32 LtdQ3 Results
Ten Lifestyle Group PLCHalf Year Results
Tuesday 23 April 
Alliance Pharma PLCFull Year Results
Alphawave IP Group PLCFull Year Results
Anglo American PLCTrading Statement
ASA International Group PLCFull Year Results
Associated British Foods PLCHalf Year Results
Eleco PLCFull Year Results
GB Group PLCTrading Statement
Jupiter Fund Management PLCTrading Statement
Maintel Holdings PLCFull Year Results
Property Franchise Group PLCFull Year Results
Taylor Wimpey PLCTrading Statement
tinyBuild IncFull Year Results
Trellus Health PLCFull Year Results
Wednesday 24 April 
1Spatial PLCFull Year Results
abrdn PLCTrading Statement
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
Lloyds Banking Group PLCQ1 Results
Nichols PLCTrading Statement
PensionBee Group PLCFirst Quarter Results
PZ Cussons PLCTrading Statement
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Serica Energy PLCFull Year Results
Star Energy Group PLCFull Year Results
Tortilla Mexican Grill PLCFull Year Results
Tracsis PLCHalf Year Results
Warpaint London PLCFull Year Results
Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Hikma Pharmaceuticals PLCTrading Statement
Focusrite PLCHalf Year Results
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
16 Apr 2024 09:48

LONDON BROKER RATINGS: RBC raises Admiral; Barclays cuts Phoenix Group

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
16 Apr 2024 09:30

Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains

INGELHEIM, Germany, April 16 (Reuters) - Boehringer Ingelheim on Tuesday overtook Bayer as Germany's largest drugmaker when the unlisted company reported a currency-adjusted gain in 2023 pharmaceutical sales of 10.3% to 20.8 billion euros ($22.11 billion).

Read more
16 Apr 2024 08:39

AstraZeneca's hails Imfinzi survival data on cancer form

(Alliance News) - AstraZeneca PLC on Tuesday said that its immunotherapy Imfinzi showed positive survival rate in people with advanced biliary tract cancer.

Read more
12 Apr 2024 12:55

EU regulator rules out link between weight-loss drugs and suicidal thoughts

April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.